<DOC>
	<DOCNO>NCT00788957</DOCNO>
	<brief_summary>This study global , multicenter , open-label phase 1b randomize , double-blinded , 2 part , phase 2 study design evaluate safety efficacy rilotumumab ganitumab combination panitumumab versus panitumumab alone patient metastatic colorectal cancer whose tumor wild-type KRAS status .</brief_summary>
	<brief_title>Panitumumab Combination Study With Rilotumumab Ganitumab Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog ( KRAS ) Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description>This study consist 3 part : Part 1 : determination tolerable dose rilotumumab combination panitumumab administer Part 2 . Part 2 : Comparison safety efficacy rilotumumab ganitumab combination panitumumab versus panitumumab alone . In Part 2 , participant randomize 1:1:1 3 cohort : 6 mg/kg panitumumab plus 10 mg/kg rilotumumab , 6 mg/kg panitumumab plus 12 mg/kg ganitumab , 6 mg/kg panitumumab placebo ( panitumumab alone cohort ) . Panitumumab administer open-label , rilotumumab ganitumab double-blinded . Part 3 : Exploratory evaluation safety efficacy rilotumumab ganitumab monotherapy follow treatment panitumumab Part 2 . In Part 3 , eligible participant terminate panitumumab treatment Panitumumab Alone arm Part 2 due disease progression intolerability could randomize 1:1 2 double-blind cohort : 10 mg/kg rilotumumab 12 mg/kg ganitumab . Participants permanently discontinue investigational product complete safety follow-up visit 30 day follow-up visit 60 day last dose investigational product . Participants follow radiographic disease progression survival every 3 month 30-day safety follow-up visit 2 year last participant enrol Part 2 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>metastatic adenocarcinoma colon rectum wildtype KRAS tumor status radiographic evidence disease progression follow treatment irinotecan and/or oxaliplatin contain chemotherapy mCRC measurable disease &gt; /= 20 mm per Response Evaluation Criteria In Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 adequate laboratory value history central nervous system ( CNS ) metastases history another primary cancer , unless : curatively resect nonmelanomatous skin cancer curatively treat cervical carcinoma situ primary solid tumor treat curative intent know active disease present &gt; /= 5 year prior treatment antiepithelial growth factor receptor ( EGFR ) , hepatocyte growth factor receptor ( HGFR , cMET ) , and/or insulinlike growth factor receptor ( IGFR ) inhibitor prior treatment AMG 102 AMG 479 prior treatment chemotherapy radiotherapy &lt; /= 21 day prior treatment target therapy &lt; /= 30 day know allergy hypersensitivity panitumumab , AMG 102 , AMG 479 history interstitial lung disease clinically significant cardiovascular disease &lt; /= 1 year active inflammatory bowel disease know human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B infection comorbid disease condition could increase risk toxicity serious nonhealing wound &lt; /= 35 day uncontrolled concurrent illness history medical condition could interfere interpretation study result major surgical procedure &lt; /= 35 day minor surgical procedure &lt; /= 14 day investigational procedure drug &lt; /= 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>panitumumab</keyword>
	<keyword>vectibix</keyword>
	<keyword>AMG 102</keyword>
	<keyword>AMG 479</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>EGFR inhibitor</keyword>
	<keyword>IGF inhibitor</keyword>
	<keyword>c-MET inhibitor</keyword>
</DOC>